Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Jan 30, 2024 4:56pm
127 Views
Post# 35853617

RE:RE:RE:RE:RE:RE:RE:ANTICIPATED PRODUCT LINE PRESS RELEASE

RE:RE:RE:RE:RE:RE:RE:ANTICIPATED PRODUCT LINE PRESS RELEASEThe bottom line here is that the market doesn't believe they will launch these plans.

At present, I am not entirely sure they even care. The low price attracts a sweet deal during negotiations.

Normally, when news like we have seen over the past several weeks comes out, existing shareholders jump in and buy more. And the price certainly goes up because they believe that plans will become reality. Normally is when the shareholders trust and support their CEO.

Unfortunately the CEO may in fact be directing teams and resources to the big strategic imperative but only the horses behind the barn can see what is going on.All we have to go on is whether we believe the strategy to produce their own products and get anti aging and maybe cellulite treatment on the street, and I for one think this is exactly the type of real action that is needed.

1. They have secured some capital to keeps lights on and fund a human capital trial for cellulite. Why the F this was not confirmed in a news release is beyond me. Launching a human trial on an emerging biotech is a GD MATERIAL EVENT.

2. They have the marketing developed to attract initial attention. Why the F they are not leveraging top web site development talent, which I would argue is available of they simply called one of their own shareholders who could rock that space is beyond me. That would move them out of amateur hour.

3. We all have the Allergan launch to look forward to which is going to drive up our price in my view, so that's a big check mark.

4. We wait to see if equity is raised for the Sirona Laboratories. If there is a major injection of equity investment, that is an absolute punch we need and nobody will be able to ignore that benefit because the share price is already in the dumpster. Any heart beat in that lane is going to produce a net positive reaction.

5. They need someone with some credibility to run Sirona Laboratories and any structure that sends a cheque our way (ie dividends to the Sirona ownership stake) would be absolutely awesome.
<< Previous
Bullboard Posts
Next >>